Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams and drug development consultants, Andy is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company.

Andy has over 15 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain. Additionally, Andy has served on the board of directors of the Controlled Release Society, most recently as secretary.

Prior to joining Quotient Sciences, Andy was Director of Novel Drug Delivery Technologies at Ipsen. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.